Evidence map›Paper›PMID 39217147›Full record

ArticleNature communications2024

Leveraging multiple data types for improved compound-kinase bioactivity prediction.

Ryan Theisen, Tianduanyi Wang, Balaguru Ravikumar, Rayees Rahman, Anna Cichońska

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ryan TheisenHarmonic Discovery Inc., New York City, NY, USA. rayees@harmonicdiscovery.com.
Tianduanyi WangHarmonic Discovery Inc., New York City, NY, USA.
Balaguru RavikumarHarmonic Discovery Inc., New York City, NY, USA.
Rayees Rahman *Harmonic Discovery Inc., New York City, NY, USA.
Anna Cichońska *Harmonic Discovery Inc., New York City, NY, USA. anna@harmonicdiscovery.com.ORCID 0000-0003-1072-8858

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Machine learning provides efficient ways to map compound-kinase interactions. However, diverse bioactivity data types, including single-dose and multi-dose-response assay results, present challenges. Traditional models utilize only multi-dose data, overlooking information contained in single-dose measurements. Here, we propose a machine learning methodology for compound-kinase activity prediction that leverages both single-dose and dose-response data. We demonstrate that our two-stage approach yields accurate activity predictions and significantly improves model performance compared to training solely on dose-response labels. This superior performance is consistent across five diverse machine learning methods. Using the best performing model, we carried out extensive experimental profiling on a total of 347 selected compound-kinase pairs, achieving a high hit rate of 40% and a negative predictive value of 78%. We show that these rates can be improved further by incorporating model uncertainty estimates into the compound selection process. By integrating multiple activity data types, we demonstrate that our approach holds promise for facilitating the development of training activity datasets in a more efficient and cost-effective way.

Indexed as

Machine LearningAlgorithmsDose-Response Relationship, DrugDrug DiscoveryHumansPhosphotransferasesProtein Kinase InhibitorsPhosphotransferasesProtein Kinase Inhibitors

Identifiers

PMID39217147
PMCPMC11365929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.